Waldenström's macroglobulinemia history and symptoms: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Many patients with Waldenström macroglobulinemia are [[asymptomatic]]. The disease is subtle and symptoms are nonspecific. The most common symptoms of Waldenström macroglobulinemia include [[weakness]], [[anorexia]], [[Blurred vision|blurry vision]], [[peripheral neuropathy]], and [[weight loss]]. Less common symptoms of the disease include [[bleeding]] and [[Raynaud's phenomenon|Raynaud phenomenon]].
Many patients with Waldenström macroglobulinemia are [[asymptomatic]]. The disease is subtle and symptoms are nonspecific, but the most common symptoms of Waldenström macroglobulinemia include [[weakness]], [[anorexia]], [[Blurred vision|blurry vision]], [[peripheral neuropathy]], and [[weight loss]]. Less common symptoms of the disease include [[bleeding]] and [[Raynaud's phenomenon|Raynaud phenomenon]].


==History and Symptoms==
==History and Symptoms==


=== History ===
=== History ===
* The onset of Waldenström macroglobulinemia is insidious and nonspecific.
* The onset of Waldenström macroglobulinemia is insidious and non-specific.
* Approximately 25% of patients with WM are asymptomatic upon presenation; their diagnosis is often made [[Incidental finding|incidentally]] from routine blood tests.<ref name="pmid11736938">{{cite journal| author=García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al.| title=Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. | journal=Br J Haematol | year= 2001 | volume= 115 | issue= 3 | pages= 575-82 | pmid=11736938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11736938  }} </ref>
* Approximately 25% of patients with WM are asymptomatic upon presentation; their diagnosis is often made [[Incidental finding|incidentally]] from routine blood tests.<ref name="pmid11736938">{{cite journal| author=García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al.| title=Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. | journal=Br J Haematol | year= 2001 | volume= 115 | issue= 3 | pages= 575-82 | pmid=11736938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11736938  }} </ref>
* Symptoms develop depending on the tissues involved in the malignant cell infiltration or [[IgM]] deposition.<ref name="pmid10623712">{{cite journal| author=Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M| title=Waldenström's macroglobulinemia: clinical features, complications, and management. | journal=J Clin Oncol | year= 2000 | volume= 18 | issue= 1 | pages= 214-26 | pmid=10623712 | doi=10.1200/JCO.2000.18.1.214 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10623712  }} </ref>
* Symptoms develop depending on the tissues involved in the malignant cell infiltration or [[IgM]] deposition.<ref name="pmid10623712">{{cite journal| author=Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M| title=Waldenström's macroglobulinemia: clinical features, complications, and management. | journal=J Clin Oncol | year= 2000 | volume= 18 | issue= 1 | pages= 214-26 | pmid=10623712 | doi=10.1200/JCO.2000.18.1.214 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10623712  }} </ref>



Revision as of 20:09, 23 January 2019

Waldenström's macroglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Bone Marrow Aspiration and Biopsy

Electrophoresis and Immunofixation

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Waldenström's macroglobulinemia history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Waldenström's macroglobulinemia history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Waldenström's macroglobulinemia history and symptoms

CDC on Waldenström's macroglobulinemia history and symptoms

Waldenström's macroglobulinemia history and symptoms in the news

Blogs on Waldenström's macroglobulinemia history and symptoms

Directions to Hospitals Treating Waldenström's macroglobulinemia

Risk calculators and risk factors for Waldenström's macroglobulinemia history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roukoz A. Karam, M.D.[2]

Overview

Many patients with Waldenström macroglobulinemia are asymptomatic. The disease is subtle and symptoms are nonspecific, but the most common symptoms of Waldenström macroglobulinemia include weakness, anorexia, blurry vision, peripheral neuropathy, and weight loss. Less common symptoms of the disease include bleeding and Raynaud phenomenon.

History and Symptoms

History

  • The onset of Waldenström macroglobulinemia is insidious and non-specific.
  • Approximately 25% of patients with WM are asymptomatic upon presentation; their diagnosis is often made incidentally from routine blood tests.[1]
  • Symptoms develop depending on the tissues involved in the malignant cell infiltration or IgM deposition.[2]

Common Symptoms

Common symptoms of Waldenström macroglobulinemia include:[1][3]

Less Common Symptoms

Less common symptoms of Waldenström macroglobulinemia include:[1][3]

Symptoms Secondary to Hyperviscosity

Hyperviscosity syndrome occurs due to the accumulation of monoclonal IgM proteins in the blood.

Clinical manifestations of hyperviscosity syndrome occur only if serum viscosity is >4 centipoises and include:[1]

References

  1. 1.0 1.1 1.2 1.3 García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A; et al. (2001). "Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases". Br J Haematol. 115 (3): 575–82. PMID 11736938.
  2. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M (2000). "Waldenström's macroglobulinemia: clinical features, complications, and management". J Clin Oncol. 18 (1): 214–26. doi:10.1200/JCO.2000.18.1.214. PMID 10623712.
  3. 3.0 3.1 Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G; et al. (2003). "Prognostic factors in symptomatic Waldenstrom's macroglobulinemia". Semin Oncol. 30 (2): 211–5. doi:10.1053/sonc.2003.50064. PMID 12720138.

Template:WH Template:WS